The fight against leukemia, particularly MLL-rearranged types, has seen significant advancements with the development of targeted therapies. Central to this progress is the role of specialized pharmaceutical intermediates that enable the creation of these cutting-edge drugs. One such crucial compound is Pinometostat, also known by its development code EPZ-5676 and CAS number 1380288-87-8.

Pinometostat is a potent and highly selective inhibitor of DOT1L (Histone Lysine Methyltransferase DOT1L). This enzyme plays a critical role in epigenetic regulation, and its aberrant activity is strongly implicated in certain leukemias, especially those with MLL gene rearrangements. By inhibiting DOT1L, Pinometostat can reverse the abnormal histone methylation patterns that drive cancer cell proliferation.

For researchers and pharmaceutical companies involved in oncology drug development, sourcing high-quality Pinometostat is paramount. As a leading manufacturer and supplier in China, we provide this essential pharmaceutical intermediate with guaranteed purity and consistent quality. Our manufacturing processes are designed to meet the rigorous standards required for pharmaceutical research, ensuring that your experiments and drug development pipelines are supported by reliable raw materials.

Why Choose Our Pinometostat (EPZ-5676) from China?

  • Targeted Therapeutic Potential: Pinometostat's ability to selectively inhibit DOT1L makes it a prime candidate for developing targeted therapies against MLL-fusion leukemia. Its efficacy in preclinical studies, demonstrating the reduction of key oncogenic genes like HOXA9 and MEIS1, underscores its therapeutic promise.
  • Reliable Supply Chain: As a dedicated pharmaceutical intermediate supplier, we understand the importance of a stable supply. We ensure that researchers and manufacturers can reliably buy Pinometostat in the quantities they need, from laboratory scale to larger production runs.
  • Expertise in Synthesis: Our team possesses deep expertise in synthesizing complex organic molecules. This allows us to deliver Pinometostat with exceptional purity, essential for accurate research outcomes and effective drug formulation.
  • Competitive Pricing: By sourcing directly from our manufacturing facility in China, you benefit from competitive pricing without compromising on quality. We aim to make advanced pharmaceutical intermediates accessible to researchers globally.

Incorporating Pinometostat into your research can accelerate your understanding of epigenetic mechanisms in cancer and pave the way for new therapeutic strategies. We invite you to contact us to learn more about our production capabilities, request a detailed quotation for Pinometostat (CAS 1380288-87-8), and discuss your specific requirements. Partner with us, a trusted pharmaceutical intermediate manufacturer, to advance your leukemia research.